Caspase-14 Antibody - BSA Free

Western Blot: Caspase-14 Antibody [NB100-56126] - Analysis of Caspase-14. Tissue lysates (50 ug/lane) and recombinant human Caspase-14 were (Hu C14, 15 ng) were western blotted with Caspase-14 antibody at 1:2000. The antibody detected both the proform of caspase-14, and the large and small subunits of active/cleaved caspase-14.

Immunohistochemistry: Caspase-14 Antibody [NB100-56126] - Tissue sections of mouse skin at E17 stained using this antibody at 1:500.

Immunohistochemistry-Paraffin: Caspase-14 Antibody [NB100-56126] - Human ovarian cancer tissue microarray stained for Caspase-14 expression using this antibody at 1:2000. Low (A) and high (B) stage ovarian tumor tissue cores. High magnification from areas of the tissue cores (A1 and B1). Decreased Caspase-14 expression was seen in the high grade, compared to the low grade tumor. Hematoxylin-eosin counterstain.

Immunohistochemistry-Paraffin: Caspase-14 Antibody [NB100-56126] - Tissue sections of human cervix stained using this antibody at 1:2000. A. Normal cervix (squamous epithelium). B. CIN1 (low-grade squamous intraepithelial lesion, mild dysplasia). C. CIN2 (high-grade squamous intraepithelial lesion, moderate dysplasia. D. CIN3 (high-grade squamous intraepithelial lesion; severe dysplasia-carcinoma in situ. In normal cervi, caspase-14 staining was found most in the midzone layer, but was absent from the basal/parabasal cell layer where mitotically active cells are known to reside. This suggests induction of caspase-14 expression with differentiation. Caspase-14 expression declined progressively during malignant transformation as the histologic severity of the cervical atypia advanced from CIN1 to CIN3. Hematoxylin-eosin counterstain.

• Reactivity: Hu, Mu, Rt, Ca, Ma
• Applications: WB, IHC, IP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free

Caspase-14 Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit Caspase-14 Antibody - BSA Free (NB100-56126) is a polyclonal antibody validated for use in IHC, WB and IP. Anti-Caspase-14 Antibody: Cited in 5 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Recombinant full-length human Caspase-14 was used as immunogen.
• Specificity: This polyclonal antibody recognizes the proform of caspase-14 (~-28-32 kDa), and the large (~14-21 kDa) and small (~10-11 kDa) of active/cleaved caspase-14.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CASP14
• Purity: Unpurified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1:1000-1:5000
  • Immunoprecipitation 1:50-1:200
  • Western Blot 1:1000-1:2000
• Control:

  Human Brain Whole Tissue Lysate (Adult Whole Normal)
  Jurkat Staurosporine Treated / Untreated Cell Lysate

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: Whole antisera
• Preservative: 0.02% Sodium Azide
• Purity: Unpurified

Alternate Names for Caspase-14 Antibody - BSA Free

• apoptosis-related cysteine protease
• CASP14
• CASP-14
• caspase 14, apoptosis-related cysteine peptidase
• caspase 14, apoptosis-related cysteine protease
• Caspase14
• Caspase-14
• EC 3.4.22.-
• MGC119078
• MGC119079
• MICE

Background

Apoptosis, or programmed cell death, is a common property of all multicellular organisms. The current dogma of apoptosis suggests that the components of the core cell-death machinery are integral to cells and widely conserved across species. Caspases, a family of cysteinyl aspartate-specific proteases, are integral components of the cell death machinery (reviewed in Siegal, 2006; and Lavrik et al, 2005). They play a central role in the initiation and execution of apoptotic cell death and in inflammation. Caspases are typically divided into 3 major groups, depending on the structure of their prodomain and their function. Group 1: inflammatory caspases (caspases 1, 4, 5, 11, 12, 14). Group II: initiator of apoptosis caspases (caspases 2, 8, 9). Group II: effector caspases (caspases 3, 6, 7). Caspases are constitutively expressed in almost all cell types as inactive proenzymes (zymogens: enzyme precursors which require a biochemical change to become active enzymes) that are processed and activated in response to a variety of pro-apoptotic or inflammatory stimuli. The procaspases (32-56 kDa) contain four domains: an N-terminal prodomain (2-25 kDa), a large subunit (p20: 17-21 kDa), a small subunit (p10: 10-13 kDa) and a short linker region between the large and small subunits. Caspase activation involves proteolytic processing of the proenzyme at specific aspartate residues between the domains. This results in removal of the prodomain as well as the linker region and formation of a heterodimer containing one large and one small subunit (p20-p10). The active caspase is a tetramer composed of two heterodimers (p202-p102). Active caspases mediate cell death and inflammation through cleavage of particular cellular substrates that are involved in these processes. Caspase-14 activation has been implicated in keratinocyte senescence which leads to the cornified cell layer, suggesting a role for caspase-14 in epithelial cell differentiation (Pistritto et al. 2002). Terminal differentiation of keratinocytes has some features of classical apoptosis including DNA fragmentation, nuclear condensation, and induction of cross-linking transglutaminases. Tumor-specific alterations in caspase-14 expression have been found in epithelial malignancies, suggesting that caspase-14 plays a role in epithelial cell transformation. The caspase-14 NB100-56126 antibody recognizes the proform of caspase-14 (approx. 28-32 kDa), and the large (approx. 14-21 kDa) and small (approx. 10-11 kDa) of active/cleaved caspase-14.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Caspase-14 Antibody (NB100-56126)(6)

Publications using NB100-56126

• Chamcheu JC, Adhami VM, Esnault S et al. Dual inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant Delphinidin Ameliorates Psoriatic Features In-vitro and in an Imiquimod-induced Psoriasis-like Disease in Mice Antioxid. Redox Signal. 2016-07-08 [PMID: 27393705] (IF/IHC, Human)
• Murakami H, Okamura K, Aoki S et al. Association of caspase-14 and filaggrin expression with keratinization of the oral mucosa and reconstruction culture rat models. J Periodontal Res 2013-12-11 [PMID: 24329962] (IF/IHC, Rat)
• Krajewska M, Kim H, Shin E et al. Tumor-associated alterations in caspase-14 expression in epithelial malignancies. Clin Cancer Res. 2005-08-01 [PMID: 16061862] (WB, IHC-P)
  
  Details:
  WB: Fig 1C (recombinant human and mouse caspase-14 protein) and Fig 1D (various normal human tissues and tumor cell lines); IHC (paraffin), Fig 2 (continuum from human uterine normal to malignant cervix), Fig 3A (human gastric cancer), Fig 4 (human ovaria
• Krajewska M, Rosenthal RE, Mikolajczyk J et al. Early processing of Bid and caspase-6, -8, -10, -14 in the canine brain during cardiac arrest and resuscitation. Exp Neurol. 2004-10-01 [PMID: 15380478]
  
  Details:
  Antibodies cited: 1. Caspase-9 (Active/Cleaved), IMG-5705: WB: Fig 1A (recombinant human caspase-9), Fig 4A (recombinant human caspase-9, rat brain), Fig 4B-F (isolated mitochondria from rat liver or heart). Fig 5 (PC12 cells) IHC (P): Fig 2d-k (rat kidne
• Arai M, Matsuzaki T, Ihara S. Wound Closure on the Neonatal Rat Skin I. The Modulation of the Thickness of Epidermis at the Closing Incisional Wounds. CellBio 2013-01-01 (IF/IHC, Rat)
• Burger C, Shirsath N et al. Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice. Acta Derm Venereol 2017-02-10 [PMID: 28597024] (IF/IHC, Mouse)

Bioinformatics

• Gene Symbol: CASP14
• Entrez:
  • 23581(Human)
  • 12365(Mouse)
  • 299587(Rat)
• Uniprot:
  • NP_033939(Mouse)